Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
4.61 (USD) • At close June 4, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 75.622 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 6.222 | 8.559 | 2.132 | 0.537 | 0.072 |
| Gross Profit
| 67.501 | -6.222 | -8.559 | -2.132 | -0.537 | -0.072 |
| Gross Profit Ratio
| 0.893 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 121.563 | 105.05 | 85.061 | 57.155 | 24.005 | 7.35 |
| General & Administrative Expenses
| 35.171 | 32.039 | 27.323 | 15.727 | 4.005 | 0.644 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 35.171 | 32.039 | 27.323 | 15.727 | 4.005 | 0.644 |
| Other Expenses
| 0 | 0 | 0 | -0.96 | -7.68 | 0.276 |
| Operating Expenses
| 156.734 | 143.311 | 112.384 | 72.882 | 28.01 | 7.994 |
| Operating Income
| -81.112 | -143.311 | -112.384 | -72.882 | -28.01 | -7.994 |
| Operating Income Ratio
| -1.073 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 10.982 | 8.297 | 3.883 | -1.076 | -7.869 | 0.254 |
| Income Before Tax
| -70.13 | -135.014 | -108.501 | -73.958 | -35.879 | -7.74 |
| Income Before Tax Ratio
| -0.927 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 2.57 | 0.338 | -3.883 | -2.016 | 0.189 | 0.277 |
| Net Income
| -72.7 | -135.352 | -104.618 | -71.942 | -36.068 | -8.017 |
| Net Income Ratio
| -0.961 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.98 | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| EPS Diluted
| -0.98 | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| EBITDA
| -72.991 | -137.089 | -99.942 | -70.75 | -27.473 | -7.667 |
| EBITDA Ratio
| -0.965 | 0 | 0 | 0 | 0 | 0 |